Gene therapy to induce cellular resistance to HIV-1 infection: lessons from clinical trials. (Q37034622)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Gene therapy to induce cellular resistance to HIV-1 infection: lessons from clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

29 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

29 December 2019

1

Mauro Giacca

1 reference

17 August 2017

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

29 December 2019

published in

Advances in Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

29 December 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

297-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

A phase I trial of autologous CD34 hematopoietic progenitor cells transduced with an anti-HIV ribozyme

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Choosing CCR5 or Rev siRNA in HIV-1

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Lentiviral vector transduction of a dominant-negative Rev gene into human CD34 hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy. Intracellular immunization

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HIV-1 encoded candidate micro-RNAs and their cellular targets

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Human immunodeficiency virus type 1 escape from RNA interference

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy and immune restoration for HIV disease

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Genetic vaccination-induced immune responses to the human immunodeficiency virus protein Rev: emergence of the interleukin 2-producing helper T lymphocyte

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Latent reservoirs of HIV: obstacles to the eradication of virus

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Re-emergence of HIV after stopping therapy

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy insertional mutagenesis insights

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HAART's first decade: success brings further challenges

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Changes in thymic function with age and during the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Mechanisms of viral membrane fusion and its inhibition

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HIV infection of non-dividing cells: a divisive problem

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

A hammerhead ribozyme targeted to the human chemokine receptor CCR5.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Simple RNA enzymes with new and highly specific endoribonuclease activities

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Modulation of HIV-1 replication by RNA interference

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Generation of functional thymocytes in the human adult.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Stem cell transplantation and gene therapy for HIV-related lymphomas

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene transfer in humans using a conditionally replicating lentiviral vector

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Intracellular antibodies and challenges facing their use as therapeutic agents

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Ribozymes in gene therapy of HIV-1.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Long-term survival and concomitant gene expression of ribozyme-transduced CD4 T-lymphocytes in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Functional dissection of the HIV-1 Rev trans-activator—Derivation of a trans-dominant repressor of Rev function

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Nuclear organization and the control of HIV-1 transcription

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

RNA-mediated inhibition of HIV in a gene therapy setting

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Transduction of human CD34 cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Preferential survival of CD4 T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Lentiviral-mediated delivery of siRNAs for antiviral therapy

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Genotoxicity of retroviral integration in hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

De novo T-cell generation in patients at different ages and stages of HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

siRNA-directed inhibition of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Regulation of human immunodeficiency virus 1 transcription by nef microRNA.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Latency in human immunodeficiency virus type 1 infection: no easy answers

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34( ) cells

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Direct evidence for thymic function in adult humans

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Chemokine receptors: multifaceted therapeutic targets

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HIV-l and the microRNA-guided silencing pathway: an intricate and multifaceted encounter

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Intracellular antibodies (intrabodies) for gene therapy of infectious diseases

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

RNAi as a treatment for HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Ribozymes as potential anti-HIV-1 therapeutic agents.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HIV-1 integration in the human genome favors active genes and local hotspots

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

RNA interference--2001.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 T cells

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Current status of gene therapy strategies to treat HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Silencing of HIV-1 with RNA interference: a multiple shRNA approach

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy: X-SCID transgene leukaemogenicity

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Suppression of microRNA-silencing pathway by HIV-1 during virus replication

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Expanding small RNA interference

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy progress and prospects: novel gene therapy approaches for AIDS.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Gene therapy: therapeutic gene causing lymphoma

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

Transcription start regions in the human genome are favored targets for MLV integration

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(07)56010-2

7 January 2021

10.1016/S1054-3589(07)56010-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086416 AND SRC:MED&resulttype=core&format=json

29 December 2019

1 reference